Equillium, Inc. (EQ) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
9.03
↑+341% vs avg
5yr avg: 2.05
30Y Low1.1·High5.0
ROE
↓
-94.0%
↑-29% vs avg
5yr avg: -73.1%
30Y Low-127%·High-39%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
EQ Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Equillium, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $271M | $142M | $26M | $25M | $36M | $109M | $109M | $59M | $99M | — |
| Enterprise Value | $241M | $113M | $9M | $3M | $-13170378 | $70M | $95M | $55M | $71M | — |
| P/E Ratio → | -7.21 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 0.64 | 0.70 | 2.27 | — | — | — | — | — |
| P/B Ratio | 9.03 | 4.98 | 1.39 | 1.11 | 1.12 | 1.63 | 1.56 | 1.40 | 1.53 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
EQ EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 0.21 | 0.08 | -0.84 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
EQ Profitability
Margins and return-on-capital ratios measuring operating efficiency
Operating margins have expanded from -40.2% to -20.1% over the past 3 years, signaling improving operational efficiency. A negative ROE of -94.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | 100.0% | 100.0% | — | — | — | — | — |
| Operating Margin | — | — | -20.1% | -40.2% | -393.9% | — | — | — | — | — |
| Net Profit Margin | — | — | -19.6% | -37.0% | -396.1% | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -94.0% | -94.0% | -38.8% | -48.9% | -126.8% | -57.2% | -53.4% | -47.9% | -42.3% | — |
| ROA | -77.9% | -77.9% | -21.2% | -20.7% | -76.2% | -45.6% | -42.3% | -41.7% | -35.7% | -31.6% |
| ROIC | -8885.0% | -8885.0% | -804.9% | -6017.4% | -850.5% | -67.7% | -47.1% | -53.5% | -36.6% | — |
| ROCE | -98.1% | -98.1% | -39.2% | -41.9% | -101.0% | -48.9% | -45.5% | -45.8% | -24.0% | -26.0% |
EQ Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $30M exceeds total debt of $719000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.02 | 0.04 | 0.32 | 0.18 | 0.14 | 0.23 | 0.00 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.03 | -0.93 | -0.99 | -1.53 | -0.58 | -0.20 | -0.08 | -0.44 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -24.98 | -58.29 | -35.40 | -26.13 | -90.76 | -4.18 | -4.96 |
Net cash position: cash ($30M) exceeds total debt ($719000)
EQ Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Equillium, Inc.'s current ratio of 10.32x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 1.79x to 10.32x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.32 | 10.32 | 3.93 | 1.79 | 2.40 | 9.35 | 11.76 | 14.30 | 33.12 | 12.57 |
| Quick Ratio | 10.32 | 10.32 | 3.93 | 1.79 | 2.40 | 9.35 | 11.76 | 14.30 | 33.12 | 12.57 |
| Cash Ratio | 10.32 | 10.32 | 3.55 | 1.48 | 2.22 | 9.05 | 11.34 | 13.69 | 32.50 | 12.49 |
| Asset Turnover | — | — | 1.61 | 0.71 | 0.20 | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 10.16 | 63.58 | 95.26 | — | — | — | — | — |
EQ Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Equillium, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 1.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 1.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | — |
| Shares Outstanding | — | $92M | $35M | $35M | $34M | $29M | $20M | $17M | $12M | $12M |
Peer Comparison
Compare EQ with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 EQYou | $271M | -7.2 | — | — | — | — | -94.0% | -8885.0% | — |
 IMVT | $7B | -11.9 | — | — | — | — | -64.8% | — | — |
 ARQT | $3B | -189.2 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 CABA | $491M | -1.8 | — | — | — | — | -127.0% | -429.6% | — |
 KMDA | $429M | 20.1 | 8.9 | 25.3 | 42.3% | 14.5% | 7.6% | 9.9% | 0.3 |
 RAPT | $296M | -2.3 | — | — | — | — | -77.1% | -155.7% | — |
 TGTX | $7B | 17.3 | 61.0 | — | 83.7% | 20.0% | 102.8% | 16.4% | 2.1 |
 RXST | $199M | -5.1 | — | — | 76.6% | -35.8% | -14.0% | -13.3% | — |
 ACLX | $7B | -28.3 | — | — | 70.0% | -1135.6% | -53.4% | -46.2% | — |
 BEAM | $3B | -36.3 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 PRTA | $432M | -1.8 | — | — | 61.8% | -1905.8% | -63.6% | -2099.8% | — |
| Healthcare Median | — | 23.1 | 14.4 | 19.0 | 64.0% | -4.2% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
What if you invested $1,000 in EQ 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in EQ be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs EQ Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationEQ vs IMVT — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Immunovant, Inc..
Compare NowEQ — Frequently Asked Questions
Quick answers to the most common questions about buying EQ stock.
What is Equillium, Inc.'s P/E ratio?
Equillium, Inc.'s current P/E ratio is -7.2x. This places it at the 50th percentile of its historical range.
What is Equillium, Inc.'s ROE?
Equillium, Inc.'s return on equity (ROE) is -94.0%. The historical average is -63.7%.
Is EQ stock overvalued?
Based on historical data, Equillium, Inc. is trading at a P/E of -7.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.